TLPH
TALPHERA, INC.
Company overview
- Market capitalization
- $61.77M
- Employees
- 12
- Latest publication
- 2026-09-29
About TALPHERA, INC.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Financial statements
Income Quarterly
| Metric | Q2 20262026-06-30 · USD | Q1 20262026-03-31 · USD | Q4 20252025-12-31 · USD | Q3 20252025-09-30 · USD | Q2 20252025-06-30 · USD | Q1 20252025-03-31 · USD | Q4 20242024-12-31 · USD | Q3 20242024-09-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0USD | 0USD | 0USD | 1,000USD | 0USD | 27,000USD | 6,684,000USD | 0USD |
| Cost Of Revenue | 0USD | — | — | — | — | 1,169,000USD | 1,323,000USD | 2,053,000USD |
| Gross Profit | 0USD | — | — | 1,000USD | — | -1,142,000USD | -1,323,000USD | -2,053,000USD |
| Research Development | 1,690,000USD | 1,650,000USD | 1,561,000USD | 1,803,000USD | 1,500,000USD | 1,169,000USD | 1,323,000USD | 2,053,000USD |
| Selling General Administrative | 2,234,000USD | 2,298,000USD | 1,892,000USD | 1,620,000USD | 2,193,000USD | 1,774,000USD | 1,673,000USD | 1,696,000USD |
| Total Operating Expenses | 3,924,000USD | 3,948,000USD | 3,453,000USD | 3,423,000USD | 3,693,000USD | 1,774,000USD | 1,673,000USD | 1,696,000USD |
| Operating Income | -3,924,000USD | -3,948,000USD | -3,453,000USD | -3,422,000USD | -3,693,000USD | -2,916,000USD | -2,996,000USD | -3,749,000USD |
| Total Other Income Expense Net | -388,000USD | 1,392,000USD | -319,000USD | -1,014,000USD | 204,000USD | 250,000USD | 1,126,000USD | 396,000USD |
| Discontinued Operations | 0USD | — | — | — | — | — | — | — |
| Net Income | -4,312,000USD | -2,556,000USD | -3,772,000USD | -4,436,000USD | -3,489,000USD | -2,593,000USD | -1,870,000USD | -3,353,000USD |
| Interest Income | — | 169,000USD | 203,000USD | 81,000USD | 83,000USD | 69,000USD | 103,000USD | 155,000USD |
| Net Interest Income | — | 169,000USD | 203,000USD | 81,000USD | 83,000USD | 69,000USD | 103,000USD | 155,000USD |
| Income Before Tax | — | -2,556,000USD | -3,772,000USD | -4,436,000USD | -3,489,000USD | -2,666,000USD | -1,870,000USD | -3,353,000USD |
| Net Income From Continuing Ops | — | -2,556,000USD | -3,772,000USD | -4,436,000USD | -3,489,000USD | -2,666,000USD | -1,870,000USD | -3,353,000USD |
| Ebitda | — | -3,948,000USD | -3,772,000USD | -4,436,000USD | -3,489,000USD | -2,666,000USD | -2,972,000USD | -3,725,000USD |
| Interest Expense | — | — | 0USD | 0USD | 0USD | 0USD | 788,000USD | 0USD |
| Unclassified Operating Expenses | — | — | — | — | — | -1,169,000USD | -1,323,000USD | -2,053,000USD |
| Depreciation And Amortization | — | — | — | — | — | 2,916,000USD | 24,000USD | 24,000USD |
| Income Tax Expense | — | — | — | — | — | — | 24,000USD | — |
| Ebit | — | — | — | — | — | — | -2,996,000USD | -3,749,000USD |
| Reconciled Depreciation | — | — | — | — | — | — | 0USD | 0USD |
| Tax Provision | — | — | — | — | — | — | — | 0USD |
| Source | DisclosureDeterministicFinal | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Income Yearly
| Metric | FY 20252025-12-31 · USD | FY 20242024-12-31 · USD | FY 20232023-12-31 · USD | FY 20222022-12-31 · USD | FY 20212021-12-31 · USD | FY 20202020-12-31 · USD | FY 20192019-12-31 · USD | FY 20182018-12-31 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 28,000USD | 0USD | 651,000USD | 1,771,000USD | 378,000USD | 5,416,000USD | 2,289,000USD | 2,151,000USD |
| Gross Profit | 28,000USD | -6,718,000USD | -4,895,000USD | -1,647,000USD | -2,628,000USD | -616,000USD | -4,517,000USD | -1,825,000USD |
| Research Development | 6,033,000USD | 6,718,000USD | 5,546,000USD | 1,694,000USD | 2,435,000USD | 4,017,000USD | 4,661,000USD | 13,137,000USD |
| Selling General Administrative | 7,479,000USD | 8,534,000USD | 11,994,000USD | 17,011,000USD | 30,935,000USD | 36,330,000USD | 43,927,000USD | 20,265,000USD |
| Total Operating Expenses | 13,512,000USD | 8,534,000USD | 11,994,000USD | 18,705,000USD | 15,488,000USD | 40,347,000USD | 49,688,000USD | 33,902,000USD |
| Operating Income | -13,484,000USD | -15,252,000USD | -16,889,000USD | -20,352,000USD | -18,116,000USD | -40,963,000USD | -54,205,000USD | -35,727,000USD |
| Interest Income | 436,000USD | 679,000USD | 6,736,000USD | 1,502,000USD | 3,162,000USD | 3,893,000USD | — | — |
| Interest Expense | 0USD | 394,000USD | 134,000USD | 1,116,000USD | 2,291,000USD | 3,305,000USD | 2,535,000USD | 12,558,000USD |
| Net Interest Income | 436,000USD | 285,000USD | 6,602,000USD | 386,000USD | 871,000USD | 588,000USD | — | — |
| Income Before Tax | -14,363,000USD | -13,004,000USD | -10,287,001USD | 59,138,000USD | -17,147,000USD | -40,375,000USD | -53,237,000USD | -47,147,000USD |
| Net Income | -14,290,000USD | -13,004,000USD | -18,397,000USD | 42,515,000USD | -35,099,000USD | -40,379,000USD | -53,240,000USD | -47,149,000USD |
| Net Income From Continuing Ops | -14,363,000USD | -13,004,000USD | -10,287,000USD | 59,125,000USD | -35,099,000USD | -40,379,000USD | — | — |
| Ebitda | -14,363,000USD | -15,156,000USD | -16,793,000USD | 61,901,000USD | -16,143,000USD | -35,217,000USD | -49,034,000USD | -34,014,000USD |
| Total Other Income Expense Net | -879,000USD | 2,248,000USD | 6,601,999USD | 79,490,000USD | 969,000USD | 588,000USD | 968,000USD | -11,420,000USD |
| Cost Of Revenue | — | 6,718,000USD | 5,546,000USD | 1,647,000USD | 3,006,000USD | 6,032,000USD | 6,806,000USD | 3,976,000USD |
| Unclassified Operating Expenses | — | -6,718,000USD | -5,546,000USD | — | -17,882,000USD | — | — | — |
| Ebit | — | -15,252,000USD | -16,889,000USD | 60,254,000USD | -18,116,000USD | -37,070,000USD | -50,702,000USD | -34,589,000USD |
| Depreciation And Amortization | — | 96,000USD | 96,000USD | 1,647,000USD | 1,973,000USD | 1,853,000USD | 1,668,000USD | 575,000USD |
| Reconciled Depreciation | — | 0USD | 311,000USD | 1,647,000USD | 1,973,000USD | 1,853,000USD | — | — |
| Income Tax Expense | — | — | 14,846,000USD | 13,000USD | 5,000USD | 4,000USD | 3,000USD | 2,000USD |
| Tax Provision | — | — | 0USD | 13,000USD | 5,000USD | 4,000USD | — | — |
| Selling And Marketing Expenses | — | — | — | — | — | — | 1,100,000USD | 500,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Balance sheet Quarterly
| Metric | Q2 20262026-06-30 · USD | Q1 20262026-03-31 · USD | Q4 20252025-12-31 · USD | Q3 20252025-09-30 · USD | Q2 20252025-06-30 · USD | Q1 20252025-03-31 · USD | Q4 20242024-12-31 · USD | Q3 20242024-09-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 26,806,000USD | 30,155,000USD | 29,719,000USD | 30,742,000USD | 16,515,000USD | 14,995,000USD | 18,236,000USD | 21,014,000USD |
| Cash And Equivalents | 742,000USD | — | — | — | — | — | — | — |
| Cash And Short Term Investments | 17,076,000USD | 21,108,000USD | 20,381,000USD | 21,289,000USD | 6,791,000USD | 5,388,000USD | 8,863,000USD | 11,117,000USD |
| Short Term Investments | 16,334,000USD | 17,285,000USD | 14,487,000USD | 17,832,000USD | — | — | 0USD | 0USD |
| Total Current Assets | 17,987,000USD | 21,336,000USD | 20,900,000USD | 21,923,000USD | 7,696,000USD | 6,176,000USD | 9,417,000USD | 12,195,000USD |
| Other Current Assets | 911,000USD | 228,000USD | 519,000USD | 634,000USD | 905,000USD | 788,000USD | 554,000USD | 1,078,000USD |
| Total Liabilities | 12,400,000USD | — | — | — | — | — | — | — |
| Total Current Liabilities | 4,188,000USD | 4,025,000USD | 3,809,000USD | 3,212,000USD | 2,630,000USD | 1,989,000USD | 2,647,000USD | 2,762,000USD |
| Other Current Liabilities | 3,151,000USD | — | — | — | — | — | — | — |
| Total Stockholder Equity | 14,406,000USD | 18,478,000USD | 17,035,000USD | 19,177,000USD | 6,627,000USD | 5,599,000USD | 8,000,999USD | 9,641,000USD |
| Total Equity Including Noncontrolling Interest | 14,406,000USD | — | — | — | — | — | — | — |
| Intangible Assets | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD |
| Accounts Payable | 387,000USD | 927,000USD | 544,000USD | 526,000USD | 835,000USD | 326,000USD | 670,000USD | 396,000USD |
| Common Stock | 52,000USD | 50,000USD | 49,000USD | 46,000USD | 20,000USD | 17,000USD | 17,000USD | 17,000USD |
| Retained Earnings | -478,388,000USD | -474,076,000USD | -471,520,000USD | -467,748,000USD | -463,312,000USD | -459,823,000USD | -457,230,000USD | -455,360,000USD |
| Total Liab | — | 11,677,000USD | 12,684,000USD | 11,565,000USD | 9,888,000USD | 9,396,000USD | 10,235,001USD | 11,373,000USD |
| Other Current Liab | — | 3,098,000USD | 3,265,000USD | 2,686,000USD | 1,795,000USD | 1,663,000USD | 1,977,000USD | 2,366,000USD |
| Capital Stock | — | 50,000USD | 49,000USD | 46,000USD | 20,000USD | 17,000USD | 17,000USD | 17,000USD |
| Cash | — | 3,823,000USD | 5,894,000USD | 3,457,000USD | 6,791,000USD | 5,388,000USD | 8,863,000USD | 11,117,000USD |
| Net Debt | — | -3,823,000USD | 605,000USD | 3,042,000USD | -6,791,000USD | -5,388,000USD | -2,336,000USD | -4,590,000USD |
| Common Stock Shares Outstanding | — | 42,410,711shares | 42,410,711shares | 41,453,382shares | 34,530,377shares | 26,268,209shares | 26,238,000shares | 26,212,902shares |
| Non Current Assets Total | — | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD |
| Non Current Liabilities Total | — | 7,652,000USD | 8,875,000USD | 8,353,000USD | 7,258,000USD | 7,407,000USD | 7,588,001USD | 8,611,000USD |
| Non Current Liabilities Other | — | 6,499,000USD | 6,499,000USD | 6,499,000USD | 6,499,000USD | 6,527,000USD | 6,527,000USD | 6,527,000USD |
| Non Currrent Assets Other | — | 8,819,000USD | 8,819,000USD | 8,819,000USD | — | 8,819,000USD | 8,819,000USD | 8,818,999USD |
| Net Working Capital | — | 17,311,000USD | 17,091,000USD | 18,711,000USD | 5,066,000USD | 4,187,000USD | 6,770,000USD | 9,433,000USD |
| Unclassified Non Current Assets | — | -8,819,000USD | -8,819,000USD | -8,819,000USD | — | -8,819,000USD | -8,819,000USD | -8,818,999USD |
| Unclassified Non Current Liabilities | — | 1,153,000USD | 2,376,000USD | 1,854,000USD | — | — | 1,061,001USD | 2,084,000USD |
| Unclassified Equity | — | 492,454,000USD | 488,457,000USD | 486,833,000USD | 469,899,000USD | 465,388,000USD | 465,196,999USD | 464,967,000USD |
| Short Long Term Debt Total | — | — | 6,499,000USD | 6,499,000USD | 6,499,000USD | 6,527,000USD | 6,527,000USD | 6,527,000USD |
| Source | DisclosureDeterministicFinal | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Balance sheet Yearly
| Metric | FY 20252025-12-31 · USD | FY 20242024-12-31 · USD | FY 20232023-12-31 · USD | FY 20222022-12-31 · USD | FY 20212021-12-31 · USD | FY 20202020-12-31 · USD | FY 20192019-12-31 · USD | FY 20182018-12-31 · USD |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 29,719,000USD | 18,236,000USD | 20,395,000USD | 47,487,000USD | 77,893,000USD | 66,295,000USD | 91,356,000USD | 120,533,000USD |
| Intangible Assets | 8,819,000USD | 8,819,000USD | 8,819,000USD | 8,819,000USD | — | — | — | — |
| Other Current Assets | 519,000USD | 554,000USD | 2,175,000USD | 7,309,000USD | 2,588,000USD | 1,683,000USD | 1,824,000USD | 1,024,000USD |
| Total Liab | 12,684,000USD | 10,235,001USD | 6,290,000USD | 25,673,000USD | 113,786,000USD | 122,045,000USD | 132,774,000USD | 116,280,000USD |
| Total Stockholder Equity | 17,035,000USD | 8,000,999USD | 14,105,000USD | 21,814,000USD | -35,893,000USD | -55,750,000USD | -41,418,000USD | 4,253,000USD |
| Other Current Liab | 3,265,000USD | 1,977,000USD | 3,176,000USD | 5,335,000USD | 6,438,000USD | 5,045,000USD | 5,939,000USD | 4,540,000USD |
| Common Stock | 49,000USD | 17,000USD | 17,000USD | 8,000USD | 7,000USD | 98,000USD | 79,000USD | 78,000USD |
| Capital Stock | 49,000USD | 17,000USD | 17,000USD | 8,000USD | 7,000USD | 98,000USD | — | — |
| Retained Earnings | -471,520,000USD | -457,230,000USD | -444,226,000USD | -425,829,000USD | -473,584,000USD | -438,485,000USD | -398,106,000USD | -345,019,000USD |
| Cash | 5,894,000USD | 8,863,000USD | 5,721,000USD | 15,275,000USD | 7,663,000USD | 27,274,000USD | 14,684,000USD | 87,975,000USD |
| Cash And Short Term Investments | 20,381,000USD | 8,863,000USD | 9,381,000USD | 15,770,000USD | 46,630,000USD | 42,886,000USD | 66,137,000USD | 105,715,000USD |
| Total Current Assets | 20,900,000USD | 9,417,000USD | 11,556,000USD | 24,566,000USD | 50,489,000USD | 46,830,000USD | 71,688,000USD | 107,994,000USD |
| Total Current Liabilities | 3,809,000USD | 2,647,000USD | 4,512,000USD | 13,770,000USD | 18,509,000USD | 17,635,000USD | 13,611,000USD | 15,928,000USD |
| Net Debt | 605,000USD | -2,336,000USD | -5,721,000USD | -5,252,000USD | 10,958,000USD | -1,675,000USD | 107,108,000USD | 17,695,000USD |
| Short Long Term Debt Total | 6,499,000USD | 6,527,000USD | — | 10,023,000USD | 18,621,000USD | 25,599,000USD | 121,792,000USD | 105,670,000USD |
| Short Term Investments | 14,487,000USD | 0USD | 3,660,000USD | 495,000USD | 38,967,000USD | 15,612,000USD | 51,453,000USD | 17,740,000USD |
| Accounts Payable | 544,000USD | 670,000USD | 1,336,000USD | 1,256,000USD | 2,121,000USD | 2,737,000USD | 1,720,000USD | 2,070,000USD |
| Common Stock Shares Outstanding | 42,410,711shares | 25,845,639shares | 14,263,744shares | 7,406,986shares | 5,993,013shares | 4,262,850shares | 3,959,213shares | 2,920,427shares |
| Non Current Assets Total | 8,819,000USD | 8,819,000USD | 8,839,000USD | 22,921,000USD | 27,404,000USD | 19,465,000USD | 19,668,000USD | 12,539,000USD |
| Non Current Liabilities Total | 8,875,000USD | 7,588,001USD | 1,778,000USD | 11,903,000USD | 95,277,000USD | 104,410,000USD | 119,163,000USD | 100,352,000USD |
| Non Current Liabilities Other | 6,499,000USD | 6,527,000USD | — | 810,000USD | 85,369,000USD | 88,664,000USD | 92,173,000USD | — |
| Non Currrent Assets Other | 8,819,000USD | 8,819,000USD | 20,000USD | 246,000USD | 7,174,000USD | 656,000USD | 1,188,000USD | 527,000USD |
| Net Working Capital | 17,091,000USD | 6,770,000USD | 7,044,000USD | 10,796,000USD | 31,980,000USD | 29,195,000USD | — | — |
| Unclassified Non Current Assets | -8,819,000USD | -8,819,000USD | — | — | — | — | — | — |
| Unclassified Non Current Liabilities | 2,376,000USD | 1,061,001USD | 1,778,000USD | 11,093,000USD | 4,901,000USD | 2,606,000USD | 6,473,000USD | 100,352,000USD |
| Unclassified Equity | 488,457,000USD | 465,196,999USD | 458,297,000USD | 447,627,000USD | 437,677,000USD | 382,539,000USD | 356,609,000USD | 349,194,000USD |
| Current Deferred Revenue | — | — | — | 115,000USD | 86,000USD | 49,000USD | 411,000USD | 315,000USD |
| Short Term Debt | — | — | — | 7,064,000USD | 9,864,000USD | 9,853,000USD | 5,952,000USD | 11,685,000USD |
| Short Long Term Debt | — | — | — | 5,363,000USD | 8,796,000USD | 8,735,000USD | 4,630,000USD | — |
| Net Receivables | — | — | — | 309,000USD | 160,000USD | 635,000USD | 432,000USD | 401,000USD |
| Inventory | — | — | — | 1,178,000USD | 1,111,000USD | 1,626,000USD | 3,295,000USD | 854,000USD |
| Property Plant Equipment Net | — | — | — | 13,856,000USD | 20,230,000USD | 18,809,000USD | 18,480,000USD | 11,483,000USD |
| Property Plant Equipment Gross | — | — | — | 25,449,000USD | 31,016,000USD | 29,398,000USD | 28,032,000USD | — |
| Unclassified Current Liabilities | — | — | — | -5,363,000USD | -8,796,000USD | -8,784,000USD | -5,041,000USD | -2,682,000USD |
| Long Term Debt | — | — | — | — | 5,007,000USD | 13,140,000USD | 20,517,000USD | — |
| Other Assets | — | — | — | — | — | — | 1USD | — |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Cash flow Quarterly
| Metric | Q1 20262026-03-31 · USD | Q4 20252025-12-31 · USD | Q3 20252025-09-30 · USD | Q2 20252025-06-30 · USD | Q1 20252025-03-31 · USD | Q4 20242024-12-31 · USD | Q3 20242024-09-30 · USD | Q2 20242024-06-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Net Income | -2,556,000USD | -3,845,000USD | -4,436,000USD | -3,489,000USD | -2,666,000USD | -1,870,000USD | -3,353,000USD | -3,827,000USD |
| Depreciation | -84,000USD | -125,000USD | -17,000USD | — | — | 0USD | -121,000USD | 0USD |
| Stock Based Compensation | 214,000USD | 185,000USD | 152,000USD | 166,000USD | 196,000USD | 230,000USD | 234,000USD | 223,000USD |
| Other Non Cash Items | -1,093,000USD | 595,000USD | 1,077,000USD | -148,000USD | -108,000USD | -1,023,000USD | -120,000USD | -291,000USD |
| Change To Account Receivables | 0USD | — | — | 27,000USD | -27,000USD | — | — | — |
| Change In Working Capital | 249,000USD | 754,000USD | 697,000USD | 523,000USD | -892,000USD | 409,000USD | 424,000USD | -715,000USD |
| Total Cash From Operating Activities | -3,400,000USD | -2,436,000USD | -2,510,000USD | -2,948,000USD | -3,470,000USD | -2,254,000USD | -2,936,000USD | -4,610,000USD |
| Capital Expenditures | 0USD | 0USD | 0USD | 0USD | 0USD | 0USD | 0USD | 0USD |
| Free Cash Flow | -3,400,000USD | -2,436,000USD | -2,510,000USD | -2,948,000USD | -3,470,000USD | -2,254,000USD | -2,936,000USD | -4,610,000USD |
| Investments | -2,714,000USD | 3,470,000USD | -17,815,000USD | 0USD | 0USD | 0USD | 600,000USD | 5,911,000USD |
| Total Cashflows From Investing Activities | -2,714,000USD | 3,470,000USD | -17,815,000USD | — | — | — | 600,000USD | 5,911,000USD |
| Total Cash From Financing Activities | 4,043,000USD | 1,403,000USD | 16,991,000USD | 4,351,000USD | -5,000USD | 0USD | 30,000USD | 0USD |
| Issuance Of Capital Stock | 4,038,000USD | — | — | — | 0USD | 0USD | — | — |
| Change In Cash | -2,071,000USD | 2,437,000USD | -3,334,000USD | 1,403,000USD | -3,475,000USD | -2,254,000USD | -2,306,000USD | 1,301,000USD |
| Begin Period Cash Flow | 5,894,000USD | 3,457,000USD | 6,791,000USD | 5,388,000USD | 8,863,000USD | 11,117,000USD | 13,423,000USD | 12,122,000USD |
| End Period Cash Flow | 3,823,000USD | 5,894,000USD | 3,457,000USD | 6,791,000USD | 5,388,000USD | 8,863,000USD | 11,117,000USD | 13,423,000USD |
| Other Cashflows From Financing Activities | 4,043,000USD | 1,403,000USD | 16,991,000USD | — | -27,000USD | 5,884,000USD | 30,000USD | 5,911,000USD |
| Unclassified Financing Cash Flow | -4,038,000USD | — | — | 4,354,000USD | — | — | — | -5,911,000USD |
| Sale Purchase Of Stock | — | -3,000USD | 8,000USD | -3,000USD | — | -5,884,000USD | 3,000USD | — |
| Other Cashflows From Investing Activities | — | — | — | — | 2,730,000USD | 2,730,000USD | — | — |
| Change To Inventory | — | — | — | — | — | 0USD | 0USD | 0USD |
| Net Borrowings | — | — | — | — | — | 0USD | 0USD | — |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Cash flow Yearly
| Metric | FY 20252025-12-31 · USD | FY 20242024-12-31 · USD | FY 20232023-12-31 · USD | FY 20222022-12-31 · USD | FY 20212021-12-31 · USD | FY 20202020-12-31 · USD | FY 20192019-12-31 · USD | FY 20182018-12-31 · USD |
|---|---|---|---|---|---|---|---|---|
| Net Income | -14,290,000USD | -13,004,000USD | -18,397,000USD | 47,755,000USD | -35,099,000USD | -40,379,000USD | -53,240,000USD | -47,149,000USD |
| Depreciation | -142,000USD | -121,000USD | 311,000USD | 1,647,000USD | 1,973,000USD | 1,853,000USD | 1,668,000USD | 575,000USD |
| Stock Based Compensation | 699,000USD | 989,000USD | 1,729,000USD | 2,889,000USD | 4,609,000USD | 4,424,000USD | 5,057,000USD | 5,168,000USD |
| Other Non Cash Items | 1,287,000USD | -323,000USD | -1,792,000USD | -79,232,000USD | -2,498,000USD | -2,827,000USD | 11,076,000USD | 14,738,000USD |
| Change In Working Capital | 1,082,000USD | -224,000USD | -1,541,000USD | -1,390,000USD | 203,000USD | -2,288,000USD | -3,906,000USD | 1,867,000USD |
| Total Cash From Operating Activities | -11,364,000USD | -12,683,000USD | -17,492,000USD | -28,331,000USD | -30,002,000USD | -38,505,000USD | -51,180,000USD | -29,075,000USD |
| Capital Expenditures | 0USD | 0USD | -100,000USD | -364,000USD | -1,827,000USD | -1,855,000USD | -3,470,000USD | -819,000USD |
| Free Cash Flow | -11,364,000USD | -12,683,000USD | -17,592,000USD | -28,695,000USD | -31,829,000USD | -40,360,000USD | -54,650,000USD | -29,894,000USD |
| Investments | -14,345,000USD | 3,781,000USD | -528,000USD | 36,450,000USD | -26,123,000USD | 34,139,000USD | — | — |
| Total Cashflows From Investing Activities | -14,345,000USD | 3,781,000USD | -528,000USD | 36,450,000USD | -26,123,000USD | 34,139,000USD | -36,563,000USD | -10,877,000USD |
| Total Cash From Financing Activities | 22,740,000USD | 12,044,000USD | 3,466,000USD | -507,000USD | 41,514,000USD | 16,956,000USD | 14,452,000USD | 75,025,000USD |
| Change In Cash | -2,969,000USD | 3,142,000USD | -14,554,000USD | 7,612,000USD | -14,611,000USD | 12,590,000USD | -73,291,000USD | 35,073,000USD |
| Begin Period Cash Flow | 8,863,000USD | 5,721,000USD | 20,275,000USD | 12,663,000USD | 27,274,000USD | 14,684,000USD | 87,975,000USD | 52,902,000USD |
| End Period Cash Flow | 5,894,000USD | 8,863,000USD | 5,721,000USD | 20,275,000USD | 12,663,000USD | 27,274,000USD | 14,684,000USD | 87,975,000USD |
| Other Cashflows From Financing Activities | 22,740,000USD | 12,044,000USD | 26,000USD | -60,000USD | 69,000USD | 286,000USD | 553,000USD | 1,218,000USD |
| Change To Inventory | — | 0USD | 61,000USD | -107,000USD | -295,000USD | 957,000USD | -3,392,000USD | 102,000USD |
| Net Borrowings | — | 0USD | -5,416,000USD | -8,433,000USD | -8,833,000USD | — | — | — |
| Issuance Of Capital Stock | — | 0USD | 8,856,000USD | 8,225,000USD | 50,278,000USD | 21,337,000USD | — | — |
| Change To Account Receivables | — | — | -189,000USD | -149,000USD | 475,000USD | -203,000USD | -31,000USD | 1,484,000USD |
| Sale Purchase Of Stock | — | — | -22,000USD | -315,000USD | -249,000USD | -86,000USD | — | — |
| Other Cashflows From Investing Activities | — | — | 2,723,000USD | -1,687,000USD | -821,000USD | 35,994,000USD | -33,093,000USD | -10,058,000USD |
| Unclassified Operating Cash Flow | — | — | 2,198,000USD | — | — | — | -11,835,000USD | -4,274,000USD |
| Unclassified Investing Cash Flow | — | — | -2,623,000USD | 2,051,000USD | 2,648,000USD | -34,139,000USD | — | — |
| Unclassified Financing Cash Flow | — | — | 8,878,000USD | 8,301,000USD | 50,527,000USD | 16,756,000USD | 13,899,000USD | 73,807,000USD |
| Source | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy | Legacy providerLegacy |
Operating metrics
No operating metrics are currently published for this company.
Revenue breakdown
| Period | Dimension | Business / region | Revenue | Currency | Source |
|---|---|---|---|---|---|
| FY 2022Yearly · 2022-12-31 | Product | Contract And Other Collaboration | 0 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | Contract And Other Revenue | 0 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | DSUVIA | 1,588,000 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | DZUVEO | 183,000 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | License | 0 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | Non Cash Royalty | 0 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | Royalty | 0 | USD | 0001437749-23-008737 |
| FY 2022Yearly · 2022-12-31 | Product | ZALVISO | 0 | USD | 0001437749-23-008737 |
| Q3 2022Quarterly · 2022-09-30 | Product | Contract And Other Collaboration | 0 | USD | 0001437749-22-027307 |
| Q3 2022Quarterly · 2022-09-30 | Product | DSUVIA | 478,000 | USD | 0001437749-22-027307 |
| Q3 2022Quarterly · 2022-09-30 | Product | DZUVEO | 29,000 | USD | 0001437749-22-027307 |
| Q2 2022Quarterly · 2022-06-30 | Product | Contract And Other Collaboration | 0 | USD | 0001437749-22-020168 |
| Q2 2022Quarterly · 2022-06-30 | Product | DSUVIA | 444,000 | USD | 0001437749-22-020168 |
| Q2 2022Quarterly · 2022-06-30 | Product | DZUVEO | 126,000 | USD | 0001437749-22-020168 |
| Q1 2022Quarterly · 2022-03-31 | Product | Contract And Other Collaboration | 0 | USD | 0001437749-22-012491 |
| Q1 2022Quarterly · 2022-03-31 | Product | DSUVIA | 442,000 | USD | 0001437749-22-012491 |
| Q1 2022Quarterly · 2022-03-31 | Product | Non Cash Royalty | 0 | USD | 0001437749-22-012491 |
| Q1 2022Quarterly · 2022-03-31 | Product | Royalty | 0 | USD | 0001437749-22-012491 |
| Q1 2022Quarterly · 2022-03-31 | Product | ZALVISO | 0 | USD | 0001437749-22-012491 |
| FY 2021Yearly · 2021-12-31 | Product | Contract And Other Collaboration — License | 1,696,000 | USD | 0001437749-23-008737 |
| FY 2021Yearly · 2021-12-31 | Product | Contract And Other Collaboration — Non Cash Royalty | 83,000 | USD | 0001437749-23-008737 |
| FY 2021Yearly · 2021-12-31 | Product | Contract And Other Collaboration — Royalty | 28,000 | USD | 0001437749-23-008737 |
| FY 2021Yearly · 2021-12-31 | Product | Contract And Other Revenue | 6,000 | USD | 0001437749-23-008737 |
| FY 2021Yearly · 2021-12-31 | Product | DSUVIA | 735,000 | USD | 0001437749-23-008737 |
| FY 2021Yearly · 2021-12-31 | Product | DZUVEO | 0 | USD | 0001437749-23-008737 |
| FY 2021Yearly · 2021-12-31 | Product | ZALVISO | 270,000 | USD | 0001437749-23-008737 |
| Q3 2021Quarterly · 2021-09-30 | Product | Contract And Other Collaboration — License | 1,696,000 | USD | 0001437749-22-027307 |
| Q3 2021Quarterly · 2021-09-30 | Product | Contract And Other Revenue | 166,000 | USD | 0001437749-22-027307 |
| Q3 2021Quarterly · 2021-09-30 | Product | Non Cash Royalty | 0 | USD | 0001437749-22-027307 |
| Q3 2021Quarterly · 2021-09-30 | Product | Royalty | 0 | USD | 0001437749-22-027307 |
| Q3 2021Quarterly · 2021-09-30 | Product | ZALVISO | 0 | USD | 0001437749-22-027307 |
| Q1 2021Quarterly · 2021-03-31 | Product | Contract And Other Collaboration — Non Cash Royalty | 45,000 | USD | 0001437749-22-012491 |
| Q1 2021Quarterly · 2021-03-31 | Product | Contract And Other Collaboration — Royalty | 15,000 | USD | 0001437749-22-012491 |
| Q1 2021Quarterly · 2021-03-31 | Product | DSUVIA | 181,000 | USD | 0001437749-22-012491 |
| Q1 2021Quarterly · 2021-03-31 | Product | ZALVISO | 270,000 | USD | 0001437749-22-012491 |
| FY 2020Yearly · 2020-12-31 | Product | Contract And Other Collaboration — Non Cash Royalty | 242,000 | USD | 0001437749-22-005888 |
| FY 2020Yearly · 2020-12-31 | Product | Contract And Other Collaboration — Royalty | 81,000 | USD | 0001437749-22-005888 |
| FY 2020Yearly · 2020-12-31 | Product | Contract And Other Revenue | 2,572,000 | USD | 0001437749-22-005888 |
| FY 2020Yearly · 2020-12-31 | Product | DSUVIA | 1,409,000 | USD | 0001437749-22-005888 |
| FY 2020Yearly · 2020-12-31 | Product | License | 0 | USD | 0001437749-22-005888 |
| FY 2020Yearly · 2020-12-31 | Product | ZALVISO | 1,112,000 | USD | 0001437749-22-005888 |
| Q2 2020Quarterly · 2020-06-30 | Product | Amended License Agreement — Contract And Other Revenue | 2,572,000 | USD | 0001437749-21-020165 |
| Q2 2020Quarterly · 2020-06-30 | Product | Amended License Agreement — ZALVISO | 301,000 | USD | 0001437749-21-020165 |
| Q2 2020Quarterly · 2020-06-30 | Product | Contract And Other Collaboration — Non Cash Royalty | 37,000 | USD | 0001437749-21-020165 |
| Q2 2020Quarterly · 2020-06-30 | Product | Contract And Other Collaboration — Royalty | 12,000 | USD | 0001437749-21-020165 |
| Q2 2020Quarterly · 2020-06-30 | Product | DSUVIA | 2,000 | USD | 0001437749-21-020165 |
| FY 2019Yearly · 2019-12-31 | Product | Amended License Agreement — Contract And Other Revenue | 43,000 | USD | 0001437749-21-006074 |
| FY 2019Yearly · 2019-12-31 | Product | Amended License Agreement — ZALVISO | 1,453,000 | USD | 0001437749-21-006074 |
| FY 2019Yearly · 2019-12-31 | Product | Contract And Other Collaboration — Non Cash Royalty | 312,000 | USD | 0001437749-21-006074 |
| FY 2019Yearly · 2019-12-31 | Product | Contract And Other Collaboration — Royalty | 104,000 | USD | 0001437749-21-006074 |
| FY 2019Yearly · 2019-12-31 | Product | Department Of Defense | 0 | USD | 0001437749-21-006074 |
| FY 2019Yearly · 2019-12-31 | Product | Dsuvia | 377,000 | USD | 0001437749-21-006074 |
| Q3 2019Quarterly · 2019-09-30 | Product | Amended License Agreement — Contract And Other Revenue | 1,000 | USD | 0001437749-20-022799 |
| Q3 2019Quarterly · 2019-09-30 | Product | Amended License Agreement — ZALVISO | 443,000 | USD | 0001437749-20-022799 |
| Q3 2019Quarterly · 2019-09-30 | Product | Contract And Other Collaboration — Non Cash Royalty | 36,000 | USD | 0001437749-20-022799 |
| Q3 2019Quarterly · 2019-09-30 | Product | Contract And Other Collaboration — Royalty | 12,000 | USD | 0001437749-20-022799 |
| Q3 2019Quarterly · 2019-09-30 | Product | Dsuvia | 116,000 | USD | 0001437749-20-022799 |
| Q2 2019Quarterly · 2019-06-30 | Product | Amended License Agreement — Contract And Other Revenue | 70,000 | USD | 0001437749-20-017343 |
| Q2 2019Quarterly · 2019-06-30 | Product | Amended License Agreement — ZALVISO | 713,000 | USD | 0001437749-20-017343 |
| Q2 2019Quarterly · 2019-06-30 | Product | Dsuvia — Royalty | 40,000 | USD | 0001437749-20-017343 |
| Q2 2019Quarterly · 2019-06-30 | Product | Non Cash Royalty | 118,000 | USD | 0001437749-20-017343 |
| FY 2017Yearly · 2017-12-31 | Product | Collaboration Agreement Revenue | 7,143,000 | USD | 0001437749-19-004353 |
| FY 2017Yearly · 2017-12-31 | Product | Contract And Other | 852,000 | USD | 0001437749-19-004353 |
| FY 2016Yearly · 2016-12-31 | Product | Collaboration Agreement Revenue | 6,440,000 | USD | 0001437749-19-004353 |
| FY 2016Yearly · 2016-12-31 | Product | Contract And Other | 10,917,000 | USD | 0001437749-19-004353 |
Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.